Quantum-Si reported first-quarter 2026 revenue of $258,000 and said the year would focus on development and market preparation for its next-generation Proteus protein sequencing platform, which is expected to launch commercially by year-end. The company completed sequencing on fully integrated Proteus instruments during the quarter, a milestone CEO Jeff Hawkins described as a significant de-risking event. Quantum-Si increased detectable amino acids from 15 to 17 within four months and aims to detect 18 amino acids at launch and all 20 during 2026. Proteus is expected to offer advantages over the current Platinum system, including automation, higher throughput and longer peptide read lengths. The company is also developing post-translational modification analysis capabilities for the platform.

Quantum-Si, a proteomics technology company, reported first quarter 2026 revenue of $258,000 and a net loss of $21.7 million. The company announced successful sequencing on integrated Proteus instruments and sequenced its first customer samples on a prototype system, with its developmental kit now detecting 17 amino acids. Chief executive Jeff Hawkins said the company achieved automated sequencing runs on integrated Proteus instruments, bringing together instrumentation, KinetIQ Array, sequencing chemistry and data analysis. The company plans early access sites for Proteus instruments this summer ahead of commercial launch at year-end 2026. Quantum-Si held $190.4 million in cash and marketable securities as of 31 March, expected to fund operations into second quarter 2028. The company reiterated 2026 guidance of approximately $1.0 million revenue and adjusted operating expenses of $98.0 million or less.

Quantum-Si, a proteomics technology company, reported first quarter 2026 revenue of $258,000 and announced significant progress on its Proteus protein sequencing platform. The company achieved automated sequencing runs on integrated Proteus instruments and sequenced its first customer samples on prototype systems. The company's developmental sequencing kit currently detects 17 amino acids. Quantum-Si plans to launch Proteus commercially by the end of 2026, with early access sites receiving instruments this summer. First quarter net loss was $21.7 million, compared to $19.2 million in the prior year. Operating expenses decreased to $24.1 million from $25.6 million. The company held $190.4 million in cash and marketable securities as of 31 March, expected to fund operations into the second quarter of 2028. Quantum-Si reiterated 2026 guidance of approximately $1 million revenue and $98 million or less in adjusted operating expenses.